Nutex Health Inc (NUTX) Stock Forecast & Price Target
Nutex Health Inc · NASDAQ
$190.17-3.07 (-1.59%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Nutex Health Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $290.00 to $310.00, so the covering firms are broadly aligned. The average target of $300.00 sits 58% above the current $190.17. The rating mix has stayed broadly stable, with Buy-side ratings easing from 4 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $6.21 next quarter toward $27.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Nutex Health Inc.
As of Sep, 2 of 2 firms rate NUTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
NUTX EPS & revenue forecast
EPS · NEXT QUARTER
$6.21
Range $5.00 – $7.13 · 5 analysts · +284% YoY
Next period, 5 analysts expect Nutex Health Inc to earn $6.21 a share (range $5.00 – $7.13), versus $1.62 a year earlier. Full-year consensus is $27.79, growing to $27.87 the year after.
REVENUE · NEXT QUARTER
$229.8M
Range $223.8M – $239.4M · 5 analysts · +51% YoY
Revenue is expected to reach $229.8M (range $223.8M – $239.4M), +51.5% year-over-year. Full-year consensus is $872.0M, rising to $964.2M next year.
Top analysts covering Nutex Health Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on NUTX.
#1
BS
Bill Sutherland
Benchmark · Rank #45
Buy
$300.00+57.8% to target
Overall win rate
45%
+ Follow
#2
Anthony Vendetti
Maxim Group · Rank #335
Buy
$175.00-8.0% to target
Overall win rate
30%
+ Follow
#3
BH
Ben Haynor
Lake Street
Buy
$310.00+63.0% to target
Coverage
—
+ Follow
#4
AS
Anderson Schock
B. Riley Securities
Buy
$290.00+52.5% to target
Coverage
—
+ Follow
NUTX stock forecast FAQ
What is NUTX's average 12-month price target?+
The 2 analysts with a live target average $300.00 for Nutex Health Inc over the next 12 months, ranging from a $310.00 high to a $290.00 low.
Is NUTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for NUTX?+
The Street-high target is $310.00 (Lake Street), and the Street-low is $290.00 (B. Riley Securities). The average of all 2 active targets is $300.00.
How many Wall Street analysts cover NUTX?+
2 analysts have an active rating on Nutex Health Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering NUTX?+
Among analysts who currently cover NUTX, Bill Sutherland of Benchmark has the strongest overall Quantellect track record (Rank #45). Their current call is Buy with a $300.00 target.
What is Nutex Health Inc's projected EPS for next quarter?+
The consensus estimate is $6.21 per share (range $5.00 – $7.13) across 5 analysts. Full-year EPS is projected at $27.79, rising to $27.87 the following year.
How much revenue is Nutex Health Inc expected to report next quarter?+
Consensus revenue is $229.8M (range $223.8M – $239.4M). Full-year revenue is projected at $872.0M, growing to $964.2M next year.
Have analysts been upgrading or downgrading NUTX lately?+
As of Sep, 2 of 2 firms rate NUTX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their NUTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
